Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.13 USD | +9.55% | +3.51% | +35.41% |
May. 01 | Transcript : G1 Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024 | |
May. 01 | Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q1 Revenue $14.5M, vs. Street Est of $15.1M | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- Low profitability weakens the company.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+35.41% | 216M | C+ | ||
-1.17% | 104B | B+ | ||
+2.87% | 97.47B | B+ | ||
+3.99% | 22.25B | B | ||
-14.77% | 21.68B | B+ | ||
-9.05% | 18.2B | A- | ||
-39.98% | 17.02B | A- | ||
-13.21% | 16.36B | B | ||
+8.55% | 14.39B | C+ | ||
+35.75% | 12.37B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GTHX Stock
- Ratings G1 Therapeutics, Inc.